December 2025

A Big Ten Cancer Research Consortium clinical trial, BTCRC-BRE15-024, titled “A phase I/II, single arm, nonrandomized study of ribociclib, a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor inhibitor, in advanced AR-positive triple-negative breast cancer,” (SABCS Poster # PS5-02-26) will be presented by Julia Knight-Shefner, MD, of the University of Wisconsin Carbone Cancer Center, as a poster at the 2025 San Antonio Breast Cancer Symposium. Read More

Nov. 19, 2025

The Big Ten Cancer Research Consortium is pleased to announce William P. Harris, MD, as a new member of the Big Ten CRC Steering Committee. Dr. Harris is a board-certified medical oncologist at Fred Hutchinson Cancer Center and UW Medical Center and serves as an associate professor in the Division of Hematology and Oncology at the University of Washington. Read More

Dec 2, 2025

A Big Ten CRC clinical trial, BTCRC-LUN18-363, titled, “Chemo-immunotherapy followed by durvalumab and ceralasertib in treatment naïve patients with extensive-stage small cell lung cancer,” led by Muhammad Furqan, MD, formerly of the University of Iowa, was featured as a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin.  Read More

Nov. 12, 2025

The Big Ten Cancer Research Consortium is pleased to announce Gustavo Girotto, MD, as a new member of the Big Ten CRC Steering Committee. Dr. Girotto is a Clinical Professor of Internal Medicine in Hematology, Oncology, and Blood and Marrow Transplantation at the University of Iowa Holden Comprehensive Cancer Center. Read More